Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation Academic Article Article uri icon

Overview

MeSH Major

  • Infant, Very Low Birth Weight
  • Leukemoid Reaction

abstract

  • Rituximab is effective and well-tolerated palliative treatment for aggressive non-Hodgkin's lymphomas that relapse after or is refractory to autologous stem cell transplantation.

publication date

  • October 2002

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1097/00130404-200209000-00007

PubMed ID

  • 12416894

Additional Document Info

start page

  • 371

end page

  • 6

volume

  • 8

number

  • 5